1α,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells

A human myeloid leukemia cell line [HL-60] could be induced to differentiate into mature myeloid cells by 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], the active form of vitamin D3. At 10−10–10−8 M, 1α,25(OH)2D3 suppressed cell growth in a dose-dependent manner and markedly induced phagocytosis and C3 rosette formation. The potency of 1α,25(OH)2D3 in inducing differentiation was nearly equivalent to that of known synthetic inducers such as dimethyl sulfoxide, actinomycin D or a phorbol ester (12-o-tetra-decanoyl-phorbol-13-acetate). These results clearly indicate that 1α,25(OH)2D3, besides its well known biological effect in enhancing intestinal calcium transport and bone mineral mobilization activities, is involved in the cell grwoth and differentiation of HL-60 cells.

[1]  H. DeLuca,et al.  Intestinal 1,25-dihydroxyvitamin D3 binding protein: Specificity of binding , 1977, Steroids.

[2]  S. Manolagas,et al.  Studies of the internalization of vitamin D3 metabolites by cultured osteogenic sarcoma cells and their application to a non-chromatographic cytoreceptor assay for 1,25-dihydroxyvitamin D3. , 1980, Biochemical and biophysical research communications.

[3]  J. Lotem,et al.  Induction of specific changes in the surface membrane of myeloid leukemic cells by steroid hormones , 1975, International journal of cancer.

[4]  Y. Ichikawa.  Differentiation of a cell line of myeloid leukemia , 1969, Journal of cellular physiology.

[5]  M. Haussler,et al.  Basic and clinical concepts related to vitamin D metabolism and action (second of two parts). , 1977, The New England journal of medicine.

[6]  H. DeLuca,et al.  Metabolism and mechanism of action of vitamin D. , 1976, Annual review of biochemistry.

[7]  J. Eisman,et al.  1,25-Dihydroxyvitamin D3 receptor in a cultured human breast cancer cell line (MCF 7 cells). , 1980, Biochemical and biophysical research communications.

[8]  L. Sachs.  Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia , 1978, Nature.

[9]  D. Feldman,et al.  1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. , 1981, Endocrinology.

[10]  J. Eisman,et al.  Specific binding of 1,25 dihydroxyvitamin D3 in the VX2 carcinoma. , 1980, Biochemical and biophysical research communications.

[11]  W. Anthony,et al.  1,25-Dihydroxycholecalciferol--a hormonally active form of vitamin D. , 1974 .

[12]  S. Collins,et al.  Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL‐60) by compounds which induce differentiation of murine leukemia cells , 1980, International journal of cancer.

[13]  M. Haussler,et al.  Specific binding of 1alpha,25-dihydroxycholecalciferol to nuclear components of chick intestine. , 1975, The Journal of biological chemistry.

[14]  S. Collins,et al.  Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia , 1979 .

[15]  S. Collins,et al.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.